LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

Search

XBiotech Inc

Uždarymo kaina

2.31

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.26

Max

2.34

Pagrindiniai rodikliai

By Trading Economics

Pajamos

21M

-5.5M

Pelnas, tenkantis vienai akcijai

-0.181

Darbuotojai

87

EBITDA

24M

-5.1M

Dividendai

By Acuity

Kitas uždarbis

2026-08-11

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-4.9M

70M

Ankstesnė atidarymo kaina

2.31

Ankstesnė uždarymo kaina

2.31

XBiotech Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Apie bendrovę XBiotech Inc

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
help-icon Live chat